Clinical trials of two KRASG12C inhibitors, MRTX849 and AMG 510, have shown robust efficacy in phase I trials including patients with non-small cell lung cancer. Data on the effectiveness of the drugs in other tumor types, such as colorectal cancer, have been more limited. Regardless, researchers are excited about the possibility of targeting proteins long thought "undruggable."

中文翻译：

---

决斗的KRASG12C抑制剂获得了回应。

两种KRASG12C抑制剂MRTX849和AMG 510的临床试验已在包括非小细胞肺癌患者在内的I期试验中显示出强大的疗效。有关药物在其他类型的肿瘤（例如结直肠癌）中有效性的数据更加有限。无论如何，研究人员对靶向长期以来被认为“无法忍受”的蛋白质的可能性感到兴奋。